Five-year overall survival and overall survival by tumor response measures from the phase 3 Himalaya study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma Meeting Abstract

  


Authors: Rimassa, L.; Chan, S.; Sangro, B.; Lau, G.; Kudo, M.; Breder, V.; Varela, M.; Crysler, O.; Bouattour, M.; Dao, T. V.; Faccio, A.; Furuse, J.; Jeng, L. B.; Kang, Y. K.; Kelley, R. K.; Paskow, M.; Makowsky, M.; Ran, D.; Negro, A.; Abou-Alfa, G.
Abstract Title: Five-year overall survival and overall survival by tumor response measures from the phase 3 Himalaya study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Meeting Title: Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2024): The Liver Meeting
Journal Title: Hepatology
Volume: 80
Issue: Suppl. 1
Meeting Dates: 2024 Nov 15-19
Meeting Location: San Deigo, CA
ISSN: 0270-9139
Publisher: John Wiley & Sons  
Date Published: 2024-10-01
Start Page: S1407
End Page: S1408
Language: English
ACCESSION: WOS:001366004003386
PROVIDER: wos
Notes: Meeting Abstract: 1849 -- Source: Wos